Tagged With Eli Lilly

Dispensed: Change at the FDA, insurance startup financials for 2018, and the first new depression drug in 35 years


A drugmaker just released a half-price version of a life-saving diabetes medication in a bet that a lower price tag will help it escape the political crosshairs


Colorado became the first state to cap the monthly cost of insulin at $100. Here's why the life-saving drug is so expensive.



Dispensed: Why Walgreens is partnering with Microsoft, inside the Loxo-Lilly deal, and controversial young blood startups


We'll get you caught up on all the news you missed at the year's biggest healthcare investor conference


Dispensed: What we saw at JPMorgan's big healthcare investor conference



Pharma giant Eli Lilly just made an $8 billion bet on a cutting-edge scientific approach that uses DNA to treat cancer


Eli Lilly stock gets bump after positive results for its mid-stage diabetes drug trial


Drugmakers are using an unusual tactic to compete in a new class of medication treating the 38 million Americans who have migraines


A new migraine medication that's changing the way we treat a condition that affects 38 million Americans just got approved


The incredible history of insulin, a lifesaving diabetes drug that was discovered almost a century ago and is now at the center of drug pricing outrage


Allergan just got one step closer to approval for its migraine drug -- and it's part of a wave of new treatments for the condition that affects 38 million Americans



One topic dominated a Senate hearing for Trump's top healthcare pick


Democrats are going after Trump's pick to replace Tom Price and using his his history with drug prices to do it


Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine


A cheaper version of the lifesaving diabetes medication just launched in the US



Some people spend as much on insulin as their mortgage -- and drugmakers are taking note


Bernie Sanders is going after insulin makers over price hikes


JIM CRAMER: These are the best and worst stocks for 2016